Cover Story ______________________________________________________________________________________________________
▲ Alex Zürcher , Chief Operating Officer and proprietary DARPin platforms , designed to improve patients ’ lives . MP0533 is a tetraspecific T cell engager for the treatment of acute myeloid leukemia ( AML ) patients and has been in phase 1 since January 2023 . MP0533 has a unique avidity-driven mode of action which allows it to activate T cells , a key type of immune cell , to kill AML cells by targeting three antigens that are preferentially co-expressed on cancerous cells , while sparing healthy cells that normally express one or none of the targets . MP0317 , our second clinical DARPin candidate also in phase 1 , is a tumor-localized , bi-specific CD40 agonist for the treatment of patients with advanced solid tumors . MP0317 is designed to activate immune cells specifically within the tumor microenvironment by binding to FAP ( fibroblast activation protein ) on cancer-associated fibroblasts and to thereby circumvent severe toxicities in peripheral organs as seen for other CD40-directed drugs .
38